SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending amid a mix of catalysts, including an analyst upgrade from Wells Fargo citing AWS growth potential and reactions to an FTC trial over Prime subscriptions. Some community members point to an upcoming hardware event and the stock's underperformance relative to other tech giants as reasons for potential upside, while others express concern over recent price action and slowing growth.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors discuss high early trading volume and a potential price recovery, with some expressing excitement about the stock's potential. Community members are pointing to possible catalysts, including government investments and exploration licenses granted to other countries, suggesting a positive outlook for deep sea mining. Talk centers around the possibility of a Barron/Trump catalyst and the potential for the stock to reach double digits.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending following positive earnings results and forward guidance, with community members debating whether the news was already priced in after the stock's recent run-up. Analysts are actively raising price targets, citing strong AI-driven demand for memory and disciplined supply management as key drivers. Some traders are expressing caution due to the stock's overbought condition and potential for profit-taking.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SOUN is trending amid discussions about its AI-powered partnership with Red Lobster to handle phone orders, with investors speculating about future deals with major chains like McDonald's. The community is focused on the potential for a short squeeze given the high short interest and recent institutional buying, while highlighting the company's growth prospects in the expanding AI sector. Bullish sentiment is fueled by anticipation of increased revenue and potential for significant gains by year-end.

Redwire Corp. manufactures and supplies space equipment. It offers critical space solutions and reliability components for the next generation space economy with IP for solar power generation and in-space 3D printing and manufacturing. It assists its customers in solving challenges of future space missions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire ($RDW) is trending as investors discuss the recent news of the company delivering drones to Ukraine, sparking optimism about its growth in the defense sector. The community is debating whether the stock is undervalued, highlighting its price-to-sales ratio and potential for a significant uptrend. Some are speculating on future contracts and revenue from Edge Autonomy, while others are weighing the impact of past financial results and dilution concerns.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as community members discuss its potential in the AI and data center sectors, spotlighted by partners like Foxconn and Mitsubishi. A recent initial production order has sparked optimism about the company's shift from pre-revenue to a revenue-generating business. Talk centers on upcoming industry events and potential for further purchase orders that could lead to significant growth.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE.X is trending as the community rallies around the meme coin, expressing bullish sentiment and encouraging others to join. The coin is gaining attention, with some community members noting the involvement of prominent investors and highlighting its potential within the meme coin sector. The community is focused on pushing the token to the number one trending spot.

Firecoin is a digital asset inspired by the concept of the eternal flame, representing energy, resilience, and guidance. It is designed to act as a decentralized token that embodies light and strength, giving holders a sense of empowerment in the digital economy. The project’s purpose is to create a community-driven ecosystem where Firecoin symbolizes progress, illumination, and the ability to move forward regardless of challenges. By leveraging blockchain technology, Firecoin aims to provide transparency, security, and accessibility to its users while maintaining its thematic connection to the symbolic power of fire.

firecoin

FIRECOIN.X is trending as users coordinate buys, with many claiming to be "IN" before a potential breakout. Discussions also revolve around tracking the token using the Phantom wallet and its features, such as transaction monitoring and balance updates. Community members are actively seeking information on where to purchase FIRECOIN.X.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure is trending following promising updates on its Huntington's disease gene therapy, AMT-130, including Breakthrough Therapy designation from the FDA. The community is discussing the potential for accelerated approval and speculating on upcoming clinical data readouts. Despite some concerns about management and past performance, analysts are weighing in on the stock.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

ATAI Life Sciences N.V.

ATAI is trending due to positive Phase 2a trial results for its BPL-003 drug in treatment-resistant depression, with analysts reiterating buy ratings and the community discussing potential FDA fast-track status. Investors are debating the significance of the trial size and upcoming catalysts, while some are drawing comparisons to other high-growth stocks and anticipating further data releases.  Discussions also involve potential M&A activity and the broader landscape of psychedelic medicine.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Should You Invest in the VanEck Biotech ETF (BBH)?

ASL Strategic Value Fund is calling for shareholders of Avadel Pharmaceuticals to vote out the company’s entire board of directors.According to a letter viewed by&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/avadel-shareholder-seeks-ousting-drugmakers-entire-board-fa071ead">The Wall Street Journal</a>, ASL alleges that Avadel mishandled the launch of its key drug, Lumryz, resulting in the company missing out on hundreds of millions of dollars in potential revenue.&nbsp;The investment firm reportedly plans to vote its $15 million stake against all of Avadel’s director nominees at the company’s annual meeting scheduled for late July.The company has been involved in litigation with its main competitor in narcolepsy, Jazz Pharmaceuticals, over patent disputes.In the letter, ASL called on Avadel to issue contingent-value rights (CVRs) to shareholders, which are future payouts tied to possible legal settlements or damages.&nbsp;One of Avadel’s ongoing cases seeks damages in excess of $1 billion.ASL further reiterates its previous demand, first made in February, that Avadel hire an investment bank to explore strategic alternatives, including a potential sale of the company.In response, a spokesperson for Avadel said the board proactively engages with shareholders and that its directors have made personal investments in the company.&nbsp;The company spokesperson further noted that the company continues to focus on “unlocking the full value of Lumryz.”In May, Avadel reported better-than-expected first-quarter sales and raised full-year revenue guidance due to improving demand for Lumryz.The pressure on Avadel comes amid weak performance across the biopharma sector.&nbsp;<a href="https://stocktwits.com/symbol/XBI">The SPDR S&amp;P Biotech ETF</a> is down 9.3% over the past year, while the&nbsp;<a href="https://stocktwits.com/symbol/SPX">S&amp;P 500</a> has gained 5.2%.<a href="https://stocktwits.com/symbol/AVDL">Avadel</a> is a $900 million market cap stock that has seen its&nbsp;stock price rise by 16.4% over the past year.&nbsp;On Stocktwits, retail sentiment for Avadel was ‘neutral’ amid ‘low’ message volume.For updates and corrections, email newsroom[at]stocktwits[dot]com.

One of Avadel’s ongoing cases seeks damages in excess of $1 billion. Representative image via Getty Images

Avadel Pharmaceuticals Under Fire? Investor Reportedly Demands Board Ouster, Sale Talks, $1B In Damages

ASL Strategic Value Fund plans to vote its $15 million stake against all Avadel board nominees at the July meeting and is pushing for contingent-value rights tied to potential legal payouts, according to a WSJ report.

Equity

Capricor Therapeutics (CAPR) said on Tuesday that the U.S. Food and Drug Administration is not eyeing an advisory committee meeting regarding approval for its Deramiocel for the treatment of Duchenne Muscular Dystrophy (DMD) associated cardiomyopathy.Capricor shares were trading 19% higher at the time of writing.The FDA indicated that an advisory committee meeting is not required at this time, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/318/capricor-therapeutics-provides-regulatory-update-on">said</a>, while adding that its application for Deramiocel approval remains under priority review.The company said in May that the FDA is considering an advisory committee meeting, dragging down investor optimism for a possible approval.The agency is expected to decide on the approval of the drug by Aug. 31. &nbsp;Company CEO Linda Marbán said that all regulatory milestones to date have proceeded as expected, and no major issues were noted at the mid-cycle review of the application.An in-person late-cycle meeting is now scheduled for mid-July.Deramiocel is Capricor’s lead cell therapy candidate for Duchenne Muscular Dystrophy, a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.On Stocktwits, retail sentiment around Capricor stayed unchanged within the ‘extremely bullish’ territory over the past 24 hours while message volume remained ‘extremely high.’<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_12_58_45_PM_png_3f23c3492d.webp" alt="CAPR's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 24, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>CAPR's Sentiment Meter and Message Volume as of 1:00 p.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the drug getting approved early following the company’s update.<stembedurl>https://stocktwits.com/Drichman7/message/618833665</stembedurl>However, Roth Capital analyst Boobalan Pachaiyappan told investors in a research note that the FDA's intention not to require a meeting "at this time" for Deramiocel “may not necessarily be positive news.”The analyst believes a promissory advisory committee meeting would be positive, as a potential positive panel vote would put pressure on the new FDA leadership to approve deramiocel in its current form.The firm reiterates a ‘Buy’ rating and $31 price target on Capricor shares.H.C. Wainright, however, opined that even in bear case scenarios with the FDA, late-stage trial data readouts are "waiting in the wings" to further strengthen Deramiocel's overall clinical and regulatory package. The analyst believes Deramiocel's first-in-class therapeutic profile, in tandem with strong manufacturing support, will get the therapy over the finish line on expected timelines, as per TheFly.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by about 34% this year but up by about 91% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/trump-presses-congress-to-pass-tax-bill-and-get-the-deal-done-this-week-after-iran-israel-ceasefire/chm4iPpRR3L">Trump Presses Congress To Pass Tax Bill And ‘Get The Deal Done’ This Week After Iran-Israel Ceasefire</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Capricor Therapeutics Says FDA May Not Hold Advisory Committee Meeting For DMD Therapy Approval: Stock Soars But Analyst Issues Warning

The FDA has indicated that an advisory committee meeting is not required at this time, the company said, while adding that its application for Deramiocel approval remains under priority review.

Shares of Capricor Therapeutics (CAPR) tumbled 16% on Friday morning following reports that Nicole Verdun, director of the office that reviews cell and gene therapies at the Food and Drug Administration, and her deputy have been placed on administrative leave.Stat News on Wednesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.statnews.com/2025/06/18/top-gene-therapy-regulator-forced-out-at-fda/">reported</a>, citing a recording of a meeting, that Verdun and her deputy Rachael Anatol were escorted out of the agency, sending CAPR shares down on Friday morning. Verdun was the FDA's key overseer of Capricor's application for approval of its Deramiocel drug.Capricor on Friday <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/317/capricor-therapeutics-announces-positive-4-year-data-from">announced</a> positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.Deramiocel is Capricor’s lead cell therapy candidate for Duchenne Muscular Dystrophy, a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. The disease affects approximately 15,000 individuals in the United States and primarily impacts boys.Last month, Capricor announced after a mid-cycle review meeting that the FDA is on track to decide on its application by the end of August, the deadline. No significant issues or major deficiencies were noted at the time of the mid-cycle review.A late-cycle meeting is now planned for mid-July.Capricor on Friday said that after four years of continuous treatment, Deramiocel-treated patients showed preservation of cardiac function, including Left Ventricular Ejection Fraction, which is a measurement of how well the left ventricle, the heart's main pumping chamber, is working.Treatment also continued to slow the progression of skeletal muscle disease, the company said, while adding that the findings suggest that extended treatment with Deramiocel may help attenuate the progression of DMD over time.CEO Linda Marbán said that the company is moving toward potential approval of the therapy, with several key regulatory steps now completed.“Our continued dialogue with the FDA remains on track with no evidence of any delays,” she said.On Stocktwits, retail sentiment around Capricor jumped from ‘bullish’ to ‘extremely bullish’ over the past 24 hours while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:630/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_20_at_10_35_01_AM_png_6034c09f71.webp" alt="CAPR's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 20, 2025 | Source: Stocktwits" width="630" height="63"><figcaption>CAPR's Sentiment Meter and Message Volume as of 10:30 a.m. ET on June 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that, although things don't look good, the new 4-year data from the study could ‘change things’ for Capricor.<stembedurl>https://stocktwits.com/MrMarB/message/618459744</stembedurl><a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by 33% this year but has more than doubled its value over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/uniswap-uni-fair-gas/chlxZJTRRPA">Uniswap Makes Fees Someone Else’s Problem</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Capricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel Data

Capricor on Friday announced positive four-year safety and efficacy results from its ongoing mid-stage study of its cell therapy Deramiocel, which failed to cheer investors.

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest.

Shares of Capricor Therapeutics (CAPR) were in the spotlight on Wednesday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/11/3097631/0/en/Capricor-Therapeutics-Announces-Key-Regulatory-Updates-for-its-Duchenne-Muscular-Dystrophy-Program.html">announced</a> the completion of the U.S. Food and Drug Administration’s (FDA) Pre-License Inspection (PLI) of its San Diego manufacturing facility for Deramiocel.Deramiocel is the company’s lead cell therapy candidate. It is under FDA review for potential approval in the treatment of Duchenne Muscular Dystrophy (DMD), a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles.No material changes are required to the manufacturing process or the facility following the inspection, the company said.While the FDA made observations, they were primarily related to routine quality systems and documentation practices, it added.Capricor expressed confidence that the facility will meet the necessary requirements to support product licensure and commercial launch, pending approval.Capricor is now looking to present evidence in support of an approval for Deramiocel in an upcoming advisory committee meeting. While the FDA has expressed intent to hold the meeting on July 30, it is yet to be confirmed by the agency, Capricor said.Last month, the company announced after a mid-cycle review meeting that the FDA is on track to decide on its application by the end of August, the deadline. No significant issues or major deficiencies were noted at the time of the mid-cycle review.A late-cycle meeting is also planned for mid-July.On Stocktwits, retail sentiment around Capricor stayed unchanged within the ‘bullish’ territory over the past 24 hours while message volume remained ‘high’.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_11_at_11_38_14_AM_png_cc62744706.webp" alt="CAPR's Sentiment Meter and Message Volume as of 11:38 a.m. ET on Jun 11, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>CAPR's Sentiment Meter and Message Volume as of 11:38 a.m. ET on Jun 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about Deramiocel, opining that the technology has “unimaginable potential.”<stembedurl>https://stocktwits.com/snowboy/message/617558955</stembedurl><a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is down by about 10% this year but up by about 143% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-inks-812-million-deal-wth-deep-apple-therapeutics/chlaHHKRbCH">Novo Nordisk’s $812M Deal With Deep Apple Lifts Retail Mood, Chatter Spikes To High Levels</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

FDA Completes Inspection of Capricor Therapeutics Manufacturing Facility For Deramiocel Approval: Retail Sees ‘Unimaginable Potential’

Capricor expressed confidence that the facility will meet the necessary requirements to support product licensure and commercial launch, pending approval.

SPDR Series Trust - SPDR Biotech ETF

$5,000

$6,000

$7,000

$8,000

What price will Ethereum hit in 2025? 
 
*Powered by Polymarket

XBI
SPDR S&P Biotech ETF

Feed

News

Sentiment

Fundamentals

Info

Latest XBI News

XBI SPDR S&P Biotech ETF